Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vs Standard-dose Rituximab with CHOP in Male DLBCL
NCT06573645Phase 3Not yet recruiting
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06573645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06573645.